First Wave BioPharma’s CEO James Sapirstein to Present at Inaugural Roth Healthcare Opportunities Conference

Rhea-AI Summary

First Wave BioPharma (NASDAQ: FWBI) announced that James Sapirstein, Chairman, President, and CEO, will present at the Inaugural Roth Healthcare Opportunities Conference on October 6, 2022, in New York City. The presentation begins at 1.15 P.M. ET at The Yale Club. This event offers an opportunity for investors to engage with company leadership regarding its advancements in targeted therapies for gastrointestinal diseases.

First Wave BioPharma is known for its proprietary technologies aimed at treating conditions like exocrine pancreatic insufficiency and inflammatory bowel diseases.

BOCA RATON, Fla., Sept. 28, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman, President, and CEO of First Wave BioPharma, will give a presentation and take investor meetings at the Inaugural Roth Healthcare Opportunities Conference taking place October 6, 2022, in New York City.

Details of the conference are as follows:

Event:	Inaugural Roth Healthcare Opportunities Conference
Registration:	https://www.meetmax.com/sched/event_88609/conference_home.html
Date:	Thursday, October 6, 2022
Time:	1.15 P.M. ET
Location:	The Yale Club, New York City

About First Wave BioPharma, Inc.
First Wave BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company is currently advancing a therapeutic development pipeline with multiple clinical stage programs built around its two proprietary technologies – the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, and niclosamide, an oral small molecule with anti-inflammatory properties. First Wave is advancing two Phase 2 clinical programs built around adrulipase for the treatment of exocrine pancreatic insufficiency (FW-EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP). In developing adrulipase, First Wave is seeking to provide CF and CP patients with a safe and effective therapy to control EPI that is non-animal derived and offers the potential to dramatically reduce their daily pill burden. The company is also advancing multiple programs involving niclosamide, including FW-UP for ulcerative proctitis and ulcerative proctosigmoiditis, FW-UC for ulcerative colitis, and FW-CD for Crohn’s disease. First Wave BioPharma is headquartered in Boca Raton, Florida. For more information visit www.firstwavebio.com.

For more information:
First Wave BioPharma, Inc.
777 Yamato Road, Suite 502
Boca Raton, FL 33431
Phone: (561) 589-7020
info@firstwavebio.com

Media contact:
Tiberend Strategic Advisors, Inc.
David Schemelia
(609) 468-9325
dschemelia@tiberend.com

FAQ

When is the Inaugural Roth Healthcare Opportunities Conference for FWBI?

The Inaugural Roth Healthcare Opportunities Conference for FWBI is on October 6, 2022.

Who will represent FWBI at the Roth Healthcare Opportunities Conference?

James Sapirstein, the Chairman, President, and CEO, will represent FWBI at the conference.

What time is FWBI's presentation at the Roth Conference?

FWBI's presentation at the Roth Conference is scheduled for 1.15 P.M. ET.

Where is the Roth Healthcare Opportunities Conference taking place?

The Roth Healthcare Opportunities Conference is taking place at The Yale Club in New York City.

What is FWBI working on in terms of gastrointestinal therapies?

FWBI is advancing therapies for gastrointestinal diseases, including treatments for exocrine pancreatic insufficiency and inflammatory bowel diseases.